Cargando…
Development of a lytic peptide derived from BH3-only proteins
Despite great advances in cancer therapy, drug resistance is a difficult hurdle to overcome that requires development of anticancer agents with novel and effective modes of action. In a number of studies, lytic peptides have shown remarkable ability to eliminate cancer cells through a different way...
Autores principales: | Liu, Q, Zhao, H, Jiang, Y, Wu, M, Tian, Y, Wang, D, Lao, Y, Xu, N, Li, Z |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979451/ https://www.ncbi.nlm.nih.gov/pubmed/27551502 http://dx.doi.org/10.1038/cddiscovery.2016.8 |
Ejemplares similares
-
MOMP in the absence of BH3-only proteins
por: García Sáez, Ana J., et al.
Publicado: (2016) -
BH3-only proteins, Bmf and Bim, in autophagy
por: Delgado, Monica, et al.
Publicado: (2013) -
Role of BH3-only protein Bim in autoimmune and degenerative diseases
por: Bouillet, P, et al.
Publicado: (2003) -
BH3-only proteins: the thorny end of the ER stress response
por: Glab, Jason A, et al.
Publicado: (2017) -
Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein
por: Galindo-Moreno, J, et al.
Publicado: (2014)